Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1045

Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.

9:00AM-11:00AM: Abstract Number: 1042

Building LSU Uveitis Registry ( BLUR ) Study – a Review of an Academic Rheumatology Center’s Experience and Approach to Uveitis

9:00AM-11:00AM: Abstract Number: 1040

Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand

9:00AM-11:00AM: Abstract Number: 1052

Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

9:00AM-11:00AM: Abstract Number: 1049

Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern

9:00AM-11:00AM: Abstract Number: 1053

Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD) : A Single Center Study of 47 Patients- Extension Study

9:00AM-11:00AM: Abstract Number: 1055

Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression

9:00AM-11:00AM: Abstract Number: 1036

Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital

9:00AM-11:00AM: Abstract Number: 1044

Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center

9:00AM-11:00AM: Abstract Number: 1043

Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center

9:00AM-11:00AM: Abstract Number: 1041

Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center

9:00AM-11:00AM: Abstract Number: 1047

Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab

9:00AM-11:00AM: Abstract Number: 1048

Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib

9:00AM-11:00AM: Abstract Number: 1037

Relationship Between Air Quality and Sarcoidosis Inflammatory Activity

9:00AM-11:00AM: Abstract Number: 1046

Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis

9:00AM-11:00AM: Abstract Number: 1051

Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers

9:00AM-11:00AM: Abstract Number: 1050

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center

9:00AM-11:00AM: Abstract Number: 1038

STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis

9:00AM-11:00AM: Abstract Number: 1035

Study of Ocular Sarcoidosis and Clusters of Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital

9:00AM-11:00AM: Abstract Number: 1033

Systemic Treatment in Sarcoidosis. Study of 377 Patients from a Single University Hospital

9:00AM-11:00AM: Abstract Number: 1039

Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis

9:00AM-11:00AM: Abstract Number: 1054

Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients

9:00AM-11:00AM: Abstract Number: 1034

Trend of Treatment Plans, and Outcomes of Therapy in Cardiac Sarcoidosis via Analysis of Standardized Uptake Values Score and Ejection Fraction Using a Cardiac PET-CT

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].